drugset / Trial / NCT02474186

Phase II Study for Solid Metastatic Tumors

NCT02474186 ↗

Phase 2 Completed 41 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

1. To induce immunity-mediated tumor response outside the radiation field (abscopal effect) after chemo-radiation of a metastatic site in metastatic breast cancer patients. 2. To monitor the induction of a T cell response. 3. To explore the role of PET scanning to assess tumor responses/abscopal effect.

Timeline

Start
2003-04
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Background Capecitabine Small molecule — —
Background Paclitaxel Small molecule — —

Indications